Overview

FDA018-ADC Vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Status:
RECRUITING

Trial end date:
2027-06-20

Target enrollment:

Participant gender:

Summary

This is a Phase III, randomized, open-label, 2-arm, multicentre, international study assessing the efficacy and safety of FDA018-ADC compared with Investigator's Choice Chemotherapy(ICC) in participants with locally recurrent inoperable or metastatic Triple-negative Breast Cancer(TNBC) who are resistant to, or recurring during or after taxane therapy.

Phase:

PHASE3

Details

Lead Sponsor:

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Treatments:

Capecitabine
eribulin
Gemcitabine
Vinorelbine